{
    "clinical_study": {
        "@rank": "147846", 
        "arm_group": [
            {
                "arm_group_label": "stem cell transplantation therapy", 
                "arm_group_type": "Experimental", 
                "description": "umbilical cord mesenchyma stem cell transplantation through interventional procedures do in liver cirrhosis patients."
            }, 
            {
                "arm_group_label": "antiviral therapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Antiviral therapy: lamivudine, 100 mg per day (oral dose); or adefovir dipivoxil 10 mg per day (oral dose); or grace entecavir 0.5-1mg per day (oral dose); or behalftelbivudine 600 mg per day (oral dose).\nSupportive therapy are allowed to use on patients not including intravenous infusions of plasma or albumin."
            }
        ], 
        "brief_summary": {
            "textblock": "The current treatment methods of liver cirrhosis are limited ,including antiviral\n      therapy,supportive therapy and liver transplantation. Antiviral therapy and Supportive\n      therapy especially the regularly intravenous infusions of plasma or albumin are combined in\n      the clinical classical therapy treatment. In the other hand,umbilical cord mesenchyma stem\n      cell with self and directed differentiation capacity can effectively rescue experimental\n      liver failure and contribute to liver regeneration, which suggests the feasibility of stem\n      cell transplantation therapy. In this study, the safety and efficacy of umbilical cord\n      mesenchyma stem cell transplantation through interventional procedures and classical therapy\n      in patients liver cirrhosis will be evaluated and compared."
        }, 
        "brief_title": "Difference in Efficacy Between Stem Cell Transplantation and Classical Therapy in Liver Cirrhosis Patients", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Liver Cirrhosis", 
        "condition_browse": {
            "mesh_term": [
                "Liver Cirrhosis", 
                "Fibrosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will includ two research centers, the number of patients in transplantation group\n      will be 30, the number of patients in classical therapy group will be 30. All the inclusion\n      and exclusion criteria will be same and the data analysis will be complete by the\n      epidemiological commissioner."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical diagnosis of liver cirrhosis;\n\n          -  Without hepatic encephalopathy;\n\n          -  No ascites or have easily dissipated ascites;\n\n          -  Value of bilirubin is less than 100;\n\n          -  Value of albumin is greater than 16 g / L;\n\n          -  Prothrombin time is less than 21 seconds;\n\n        Exclusion Criteria:\n\n          -  Severe cardiovascular disease, and immunocompromised patients;\n\n          -  Patients with localized lesions affecting graft infection;\n\n          -  Coagulation disorders;\n\n          -  Liver nodules more than 2cm or Liver cancer."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01718587", 
            "org_study_id": "2012-10-09  TC liver cirrhosis"
        }, 
        "intervention": [
            {
                "arm_group_label": "stem cell transplantation therapy", 
                "description": "interventional procedure once", 
                "intervention_name": "stem cell transplantation through interventional procedure", 
                "intervention_type": "Procedure", 
                "other_name": "UCMSC transplantation"
            }, 
            {
                "arm_group_label": "antiviral therapy", 
                "description": "lamivudine, 100 mg per day (oral dose); or adefovir dipivoxil 10 mg per day (oral dose); or grace entecavir 0.5-1mg per day (oral dose); or behalftelbivudine 600 mg per day (oral dose).", 
                "intervention_name": "antiviral therapy (lamivudine, other antiviral drugs)", 
                "intervention_type": "Drug", 
                "other_name": "lamivudine or other antiviral drugs."
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antiviral Agents", 
                "Adefovir dipivoxil", 
                "Lamivudine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "umbilical cord mesenchyma stem cell", 
            "liver cirrhosis", 
            "antiviral therapy"
        ], 
        "lastchanged_date": "October 30, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China"
                }, 
                "name": "Yihua An"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Difference in Efficacy Between Umbilical Cord Mesenchyma Stem Cell Transplantation and Classical Therapy in Liver Cirrhosis Patients", 
        "other_outcome": [
            {
                "description": "The result of liver biopsy judged by the same one expert.", 
                "measure": "liver biopsy", 
                "safety_issue": "Yes", 
                "time_frame": "baseline,6 and 12 months after transplantation"
            }, 
            {
                "description": "Observe and photograph the related varicose veins.", 
                "measure": "gastroscopy", 
                "safety_issue": "Yes", 
                "time_frame": "baseline,6 and 12 months after treatment or transplantation"
            }
        ], 
        "overall_contact": {
            "email": "doctoran2010@hotmail.com", 
            "last_name": "Yihua An, PhD", 
            "phone": "0086-10-57976845"
        }, 
        "overall_official": {
            "affiliation": "Department of Stem Cell Transplantation, the General Hospital of Chinese People's Armed Police Force", 
            "last_name": "Yihua An, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health of Logistics Department in the Chinese People's Armed Police Force", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Instrument:universal 1.5 Tesla superconducting MRI instrument. Slice thickness :2mm.", 
                "measure": "liver volume calculated by MRI", 
                "safety_issue": "Yes", 
                "time_frame": "baseline"
            }, 
            {
                "description": "Instrument:universal 1.5 Tesla superconducting MRI instrument. Slice thickness :2mm.", 
                "measure": "change from baseline in liver volume calculated by MRI at 6 months", 
                "safety_issue": "Yes", 
                "time_frame": "6 months after treatment"
            }, 
            {
                "description": "Instrument:universal 1.5 Tesla superconducting MRI instrument. Slice thickness :2mm.", 
                "measure": "change from baseline in liver volume calculated by MRI at 12 months", 
                "safety_issue": "Yes", 
                "time_frame": "12 months after treatment"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01718587"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "alanine aminotransferase\naspartate aminotransferase\ngamma-glutamyltransferase(GGT)\nalkaline phosphatase\ntotal bilirubin\ndirect bilirubin\nThe total bile acid (TBA)\nalbumin\nthe proportion of white balls", 
                "measure": "blood biochemistry", 
                "safety_issue": "Yes", 
                "time_frame": "baseline, 1,3,6 and 12 months after treatment or transplantation"
            }, 
            {
                "description": "platelet count (PLT)\nmean platelet volume (MPV)\nplatelet distribution width (PDW)\nplatelet hematocrit (PCT)\nalpha feto protein (AFP)", 
                "measure": "blood test", 
                "safety_issue": "Yes", 
                "time_frame": "baseline,1,3,6 and 12 months after treatment or  transplantation"
            }, 
            {
                "description": "laminin (LN)\n\u2163 collagen detection (CIV)\nhyaluronic acid (HA)\nprocollagen \u2162(PC \u2162)", 
                "measure": "liver enzyme fiber spectrum", 
                "safety_issue": "Yes", 
                "time_frame": "baseline,1,3,6 and 12 months after treatment or transplantation"
            }, 
            {
                "description": "prothrombin time (PT)\nactivated partial thromboplastin time (APTT)\nfibrinogen (FIB)\nthrombin time (TT)", 
                "measure": "coagulation", 
                "safety_issue": "Yes", 
                "time_frame": "baselin,1,3,6 and 12 months after treatment or transplantation"
            }, 
            {
                "description": "1)Portal vein diameter (Dpv) 2\uff09Portal vein maximum velocity (Vmaxpv) 3\uff09Portal vein blood flow per minute (Qpv) 4) The splenic vein diameter (Dsv) 5) Splenic vein maximum flow velocity (Vmaxsv) 6) Splenic vein blood flow per minute (Qsv)", 
                "measure": "portal vein and splenic vein measure", 
                "safety_issue": "Yes", 
                "time_frame": "baseline,1,3,6 and 12 months after treatment or transplantation"
            }, 
            {
                "description": "estrogen and progestin", 
                "measure": "estrogen and progestin in blood", 
                "safety_issue": "Yes", 
                "time_frame": "baseline,1,3,6 and 12 months after treatment or  transplantation"
            }
        ], 
        "source": "General Hospital of Chinese Armed Police Forces", 
        "sponsors": {
            "collaborator": {
                "agency": "Hebei Medical University First Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "General Hospital of Chinese Armed Police Forces", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}